{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:29:53Z","timestamp":1765369793103},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,24]]},"DOI":"10.7759\/cureus.14093","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T04:34:05Z","timestamp":1616646845000},"source":"Crossref","is-referenced-by-count":3,"title":["Intestinal Perforation: A Rare Complication of Treatment With Bevacizumab"],"prefix":"10.7759","author":[{"given":"Ramesh","family":"Adhikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medha","family":"Ghose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysun","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simranjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romil","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669","article-title":"The biology of vegf and its receptors","volume":"9","author":"Ferrara N","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J. The biology of vegf and its receptors. Nat Med. 2003, 9:669-676. 10.1038\/nm0603-669","journal-title":"Nat Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0330","article-title":"Practical management of bevacizumab-related toxicities in glioblastoma","volume":"20","author":"Brandes AA","year":"2015","unstructured":"Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist. 2015, 20:166-175. 10.1634\/theoncologist.2014-0330","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9300","article-title":"Biosimilars as a future, promising solution for financial toxicity: a review with emphasis on bevacizumab","volume":"12","author":"Saleem T","year":"2020","unstructured":"Saleem T, Qurashi H, Jamali M, Chan Gomez J, Kanderi T. Biosimilars as a future, promising solution for financial toxicity: a review with emphasis on bevacizumab. Cureus. 2020, 12:e9300. 10.7759\/cureus.9300","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 who classification of tumours of the central nervous system","volume":"114","author":"Louis DN","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, et al.. The 2007 who classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109. 10.1007\/s00401-007-0243-4","journal-title":"Acta Neuropathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-996. 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the eortc-ncic trial","volume":"10","author":"Stupp R","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, et al.. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the eortc-ncic trial. Lancet Oncol. 2009, 10:459-466. 10.1016\/s1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.23.2595","article-title":"Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma","volume":"28","author":"Wick W","year":"2010","unstructured":"Wick W, Puduvalli VK, Chamberlain MC, et al.. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010, 28:1168-1174. 10.1200\/jco.2009.23.2595","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials","volume":"17","author":"Wong ET","year":"1999","unstructured":"Wong ET, Hess KR, Gleason MJ, et al.. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999, 17:2572-2578. 10.1200\/jco.1999.17.8.2572","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4137\/cmo.S8503","article-title":"Bevacizumab for the treatment of glioblastoma","volume":"7","author":"Gil-Gil MJ","year":"2013","unstructured":"Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol. 2013, 7:123-135. 10.4137\/cmo.S8503","journal-title":"Clin Med Insights Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3079-6","article-title":"Population pharmacokinetics of bevacizumab in cancer patients with external validation","volume":"78","author":"Han K","year":"2016","unstructured":"Han K, Peyret T, Marchand M, et al.. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016, 78:341-351. 10.1007\/s00280-016-3079-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman HS","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, et al..  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009, 27:4733-4740. 10.1200\/jco.2008.19.8721","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl TN","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, et al.. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009, 27:740-745. 10.1200\/jco.2008.16.3055","journal-title":"J Clin Oncol"},{"key":"ref13","unstructured":"Atezolizumab plus bevacizumab approved to treat liver cancer. (2020). Accessed. March 8th, 2021: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/fda-atezolizumab-bevacizumab-liver-cancer.."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4274\/vhd.07279","article-title":"Chronic viral hepatitis in human immunodeficiency virus-infected patients","volume":"22","author":"Sili U","year":"2016","unstructured":"Sili U, Tekin A, Korten V. Chronic viral hepatitis in human immunodeficiency virus-infected patients. J Viral Hepat. 2016, 22:39-42. 10.4274\/vhd.07279","journal-title":"J Viral Hepat"},{"key":"ref15","article-title":"Bevacizumab-induced bowel perforation","volume":"111","author":"Sliesoraitis S","year":"2011","unstructured":"Sliesoraitis S, Tawfik B. Bevacizumab-induced bowel perforation. J Am Osteopath Assoc. 2011, 111:437-441.","journal-title":"J Am Osteopath Assoc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14216\/kjco.19004","article-title":"Bevacizumab induced intestinal perforation in patients with colorectal cancer","volume":"15","author":"Baek SY","year":"2019","unstructured":"Baek SY, Lee SH, Lee SH. Bevacizumab induced intestinal perforation in patients with colorectal cancer. Korean J Clin Oncol. 2019, 15:15-18. 10.14216\/kjco.19004","journal-title":"Korean J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-071","article-title":"Colon perforation during antiangiogenic therapy for malignant glioma","volume":"11","author":"Norden AD","year":"2009","unstructured":"Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol. 2009, 11:92-95. 10.1215\/15228517-2008-071","journal-title":"Neuro Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"Gordon CR","year":"2009","unstructured":"Gordon CR, Rojavin Y, Patel M, et al.. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009, 62:707-709. 10.1097\/SAP.0b013e3181828141","journal-title":"Ann Plast Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/52953-intestinal-perforation-a-rare-complication-of-treatment-with-bevacizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:01Z","timestamp":1707506761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/52953-intestinal-perforation-a-rare-complication-of-treatment-with-bevacizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.14093","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,24]]}}}